ARB 1467

Drug Profile

ARB 1467

Alternative Names: ARB 1468; ARB-1467; TKM HBV

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference; Surface antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 03 Aug 2017 Arbutus Biopharma completes a phase II trial in Hepatitis B in USA (Parenteral)
  • 22 Apr 2017 Arbutus Biopharma plans a clinical trial to evaluate long term dosing of ARB 1467 in combination with nucleotide analog therapy, pegylated interferon or another immune modulator for Hepatitis B in the second half of 2017
  • 22 Apr 2017 Efficacy data from a phase IIa trial in Hepatitis B presented at the European Association for the Study of the Liver (EASL-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top